Merck unit sues India's Glenmark over diabetes drug

MUMBAI, April 2 Tue Apr 2, 2013 11:10am EDT

MUMBAI, April 2 (Reuters) - A unit of U.S. drugmaker Merck & Co sued India's Glenmark Pharmaceuticals on Tuesday for infringing its patent on two diabetes drugs.

The action comes a day after Swiss drugmaker Novartis AG lost a landmark court ruling over patent protection for its cancer treatment Glivec, a decision widely seen as boosting India's generic pharmaceuticals business.

Merck's Indian unit, MSD, holds an Indian patent on sitagliptin, a chemical compound sold under the Januvia and Janumet brands.

Although the patent is yet to expire, Mumbai-based Glenmark confirmed it had launched generic versions of the two drugs.

"Glenmark is a responsible company and has launched the products after due diligence and research," it said in an emailed statement.

MSD filed its case with the Delhi High Court on Tuesday, saying it was disappointed with Glenmark's decision to launch products that directly infringed its intellectual property.

There are about 65 million patients in India being treated for type 2 diabetes, MSD said.

"We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them," MSD said in an email to Reuters.

Januvia costs nearly 1,300 rupees ($23.92) for a month's dose while Glenmark has offered the drug at a discount of about 30 percent, an industry source said.

Neither company would comment on their prices.

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
czlc89 wrote:
Januvia may not be as profitable as before because there is new research showing that incretin mimetics such as Januvia and Byetta are linked to pancreatic damage and pancreatic cancer. This has been a concern for a few years, when the FDA started receiving reports of pancreatic injury with Byetta, but for the first time researchers have actually found evidence of pre-cancerous cell changes in the pancreatic tissue of patients who took these drugs. Given that the research will continue to investigate this, Januvia is probably not going to be as big of a seller as before since there are plenty of other less risky options out there.

Apr 02, 2013 2:57pm EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.